Need to Know: Panicked over Tesla? Here’s the first thing you shouldn’t do

This post was originally published on this site

The last trading day of the month is setting up as a test of the faithful—the Tesla faithful that is.

Pressure was building for the iconic car maker Friday after CEO Elon Musk got hit with a lawsuit from the SEC, which wants him out as head honcho after that now infamous taking-Tesla-private, “funding secured” tweet. Shares could be looking at their worst session in two years if premarket action is anything to go by.

From chat rooms and Twitter burning up over the topic, comes our call of the day from Ross Gerber, co-founder and CEO of Gerber Kawasaki Wealth & Investment Management, who says first and foremost, investors need to keep their cool.

“Don’t do anything emotional. First rule. Don’t let headlines scare you. The stock will go down tomorrow as it should, next week we can asses the issues more clearly with more information,” said Gerber in a tweet. He followed that up with a few more.

Gerber was getting a little flak for that tweet. Tesla was in his top five buys in the second quarter of 2018, according to 13F data, so clearly he sits on the side of the bulls. Those less in love with Tesla weren’t holding back:

As for where shares go next, Mott Capital Management founder Michael Kramer said Tesla is nearing a big support level, given the late-session losses. “Support is now around the $250 level. If the stock falls below that, it could get much worse in a hurry,” he said in a blog post. After that, he said, look for support at $180.

Here’s his chart:

Mott Capital Management

And in a case of viral stories colliding, one section of that SEC filing explains how Musk got to that $420-per-share public-to-private price tag.

“This calculation resulted in a price of $419 and Musk stated that he rounded the price up to $420 because he had recently learned about the number’s significance in marijuana culture and thought his girlfriend would ‘find it funny, which admittedly isn’t a great reason to pick a price,’” the statement said of the guy who triggered a 5% drop in shares earlier this month after appearing to smoke a reefer during an interview.

Read: Could Elon Musk’s tweets cause him to lose his job as Tesla CEO? 5 of the costliest tweets ever

Opinion: If Tesla had a real board, it would remove Elon Musk as CEO in light of SEC lawsuit

The chart

The eurozone is possibly plunging into a new crisis after Italy’s ruling antiestablishment parties pushed through a budget deficit target of 2.4%, putting the government on a collision course with the European Union. Economy Minister Giovanni Tria clearly caved in as he was looking for ballpark 1.6%.

Oon Friday, Italian stocks I945, -3.93%  were getting crushed, down nearly 4% for their worst day since early 2016, with banks like Banco BPM SpA BAMI, -10.26%  tumbling 7% in Milan. Here’s the chart of the day that shows the choppy action over the last few sessions:

MarketWatch

Painful day for Italy

The markets

Dow YMZ8, -0.31% S&P 500 ESZ8, -0.27%  and Nasdaq NQZ8, -0.33%  futures are barely budging. That is after the S&P SPX, +0.28% Dow DJIA, +0.21%  and Nasdaq COMP, +0.65%  all managed a higher close Thursday.

Plus: Banking on a stock market rally? Check out this chart first

Gold US:GCU8 is slipping, while crude US:CLU8 is steady, but looking at a solid gain for the week. The dollar DXY, +0.35% is moving up, mostly against the euro EURUSD, -0.5154% which is taking a hit on Italy budget worries. 

Europe stocks SXXP, -0.68%  are falling, dragged by those slumping Italian stocks. Japan stocks NIK, +1.36%  saw a powerful 5.5% gain for September, in what was a mostly upbeat day for Asian markets ADOW, +0.42% ADOW, +0.42%

Read: The ‘7 worst words in the world’ could signal trouble for this stock market, warns Oaktree Capital’s Howard Marks

The buzz

Eli Lilly LLY, +0.36%  says the FDA has approved the drug Emgality for preventing migraines in adults. It is one of three in a new class of drugs recently approved to revolutionize migraine treatment, all with identical $6,900 price tags.

A day after gripping testimony by judge Brett Kavanaugh and his accuser Christine Blasey Ford, attention will stay fixed on DC Friday as the Senate Judiciary Committee gets ready to vote on whether or not to move the Supreme Court nomination of Kavanaugh to the Senate floor for confirmation. Political betting market PredictIt says Kavanaugh’s odds of getting confirmed jumped after his testimony.

Read: Women contrast Christine Blasey Ford’s ‘poise’ with Brett Kavanaugh’s ‘anger’

In the U.K., former foreign secretary Boris Johnson has come up with a post-Brexit plan B, laying on the criticism over Prime Minister Theresa May’s troubled Chequers compromise.

Personal income, consumer consumption, core inflation are due ahead of the open, with the Chicago purchasing managers index and consumer sentiment expected later.

Quote of the day
Getty Images

Judge Brett Kavanaugh on Capitol Hill September 27

“The basic principles that underscore the Senate’s constitutional duty of advice and consent on federal judicial nominees require nothing less than a careful examination of the accusations and facts by the FBI.” — That was a statement from the American Bar Association, obtained by CNN, calling on the Senate Judiciary Committee to delay ruling on nominee Brett Kavanaugh until the FBI completes its probe into allegations against him.

Earlier this month, the ABA gave Kavanaugh its highest “well-qualified” rating for his nomination.

Random reads

Miracle in Micronesia. Boeing 737 crashes into the sea, all 47 people make it out

Canada politicians unanimously vote to strip Aung San Suu Kyi of honorary citizenship over Rohingya crisis

Morning Joe’s co-host Mika Brzezinski says she had to ask five times before she got a raise

Video shows the moment Dutch cops foiled a massive terrorist attack plot

In a first, man charged with drunken driving—on a scooter

Need to Know starts early and is updated until the opening bell, but sign up here to get it delivered once to your email box. Be sure to check the Need to Know item. The emailed version will be sent out at about 7:30 a.m. Eastern.

Follow MarketWatch on Twitter, Instagram, Facebook.

Providing critical information for the U.S. trading day. Subscribe to MarketWatch’s free Need to Know newsletter. Sign up here.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.